Overview
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating
extraordinary medicines for patients with serious diseases by unlocking biologically
important targets long considered undruggable. The company has pioneered a new class of
alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have
historically been beyond the reach of conventional medicines. The company’s lead
investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-
catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug
developers for decades. Zolucatetide is being evaluated in the clinic across multiple
Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous
polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide,
Parabilis is advancing additional Helicon-based programs focused on other challenging
targets where we believe our medicines could have life-altering impact.